Maegim한국어

안국약품

001540KOSDAQSector: Pharma & Biotech
₩11,560▲ 1.58%Market cap ₩150.8BAs of Jul 21, 2026 close · updated once daily
B
Grade B61.6 ptsTop 30% of 2,523 stocks
Financial strength
51.9
Growth momentum
67.6
Price attractiveness
68.5

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

51.9
How much debt does it carry relative to equity?
Debt-to-equity ratio
87.0%
✗ Below median · Top 70.9% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
164.9%
✗ Below median · Top 55.1% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
3.2%
✓ Above median · Top 36.8% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
4.5%
✓ Above median · Top 29.5% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

67.6
How much did revenue grow in a year?
Revenue growth (YoY)
13.2%
✓ Above median · Top 34% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
14.3%
✓ Above median · Top 22.3% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
46.6%
✓ Above median · Top 22.1% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
1.5%
✗ Below median · Top 51.3% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

68.5
Is the price expensive relative to earnings?
P/E (price-to-earnings)
20.2x
✓ Above median · Top 25% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.91x
✓ Above median · Top 38% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15